Maximum quantity allowed is 999
Please select the quantity
CAS RN: 112809-51-5 | Product Number: L0248
Letrozole
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole
- 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days |
|---|---|---|---|
| 1G |
$169.00
|
23 | ≥100 |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | L0248 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__7H__1__1N__5 = 285.31 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 112809-51-5 |
| Reaxys Registry Number | 6813913 |
| PubChem Substance ID | 172089003 |
| Merck Index (14) | 5450 |
| MDL Number | MFCD00866241 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 183.0 to 187.0 °C |
Properties (reference)
| Melting Point | 185 °C |
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 + H312 + H332 : Harmful if swallowed, in contact with skin or if inhaled. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P271 : Use only outdoors or in a well-ventilated area. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P302 + P352 + P312 : IF ON SKIN: Wash with plenty of water.Call a POISON CENTER/doctor if you feel unwell. P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell. P405 : Store locked up. |
Related Laws:
| RTECS# | DI4957000 |
Transport Information:
| H.S.code* | 2933.99-000 |
Application
Letrozole: A Nonsteroidal, Potent and Selective Aromatase Inhibitor
Letrozole (CGS 20267), exemestane [E0941] and anastrozole [A2370] are third generation, and potent and selective aromatase inhibitors. In postmenopausal women, estrogens are mainly derived from the action of the aromatase which is responsible enzyme for the aromatization of androgens ([A0845] and [T0027]) into estrogens ([E0026] and [E0025]) respectively in the periphery. The growth of the breast cancer is stimulated or maintained by estrogens. Letrozole, exemestane and anastrozole inhibit aromatase and estrogen synthesis, resulting in suppressing tumor growth. (The product is for research purpose only.)
References
- Highly selective inhibition of estrogen biosynthesis by CGS 20267 (Letrozole), a new non-steroidal aromatase inhibitor
- Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
- Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status
- Aromatase inhibitors in the treatment of breast cancer (a review)
- Letrozole: a review of its use in postmenopausal women with advanced breast cancer
- High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.